Menu
Science and research

Professional Publications

Author
Title
Year of publication

Publications (3663)

[261]

Belickova, M.; Vesela, J.; Jonasova, A.; Pejsova, B.; Votavova, H.; Dostalova Merkerova, M.; Zemanova, Z.; Brezinova, J.; Mikulenkova, D.; Lauermannova, M.; Valka, J.; Michalova, K.; Neuwirtova, R.; Cermak, J.

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

[year of publication 2016, impact factor 5.168 ]

[262]

Cermak, J.; Balla, J.; Jacob, H.S.; Balla, G.; Enright, H.; Nath, K.; Vercellotti, G.M.

Tumor cell heme uptake induces ferritin synthesis resulting in altered oxidant sensitivity : possible role in chemotherapy efficacy

[year of publication 2006, impact factor 5.156]

[263]

Kuželová, K.; Brault, D.

Interactions of dicarboxylic porphyrins with unilamellar lipidic vesicles : drastic effects of pH and cholesterol on kinetics

[year of publication 2006, impact factor 5.144]

[264]

Schetelig, J.; de Wreede, L.C.; Andersen, N.S.; Moreno, C.; van Gelder, M.; Vitek, A.; et al.

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: A retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)

[year of publication 2017, impact factor 5.128 ]

[265]

Olavarria, E.; Ottmann, O.G.; Deininger, M.; Clark, R.E.; Bandini, G.; Byrne, J.; Lipton, J.; Vitek, A.; Michallet, M.; Siegert, W.; Ullmann, A.; Wassmann, B.; Niederwieser, D.; Fischer, T.

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

[year of publication 2011, impact factor 5.116 ]

[266]

Ragin, C.; Liu, J.C.; Jones, G.; Shoyele, O.; Sowunmi, B.; Kennett, R.; Groen, H.J.; Gibbs, D.; Blackman, E.; Esan, M.; Brandwein, M.S.; Devarajan, K.; Bussu, F.; Chernock, R.; Chien, C.-Y.; Cohen, M.A.; El-Mofty, S.; Suzuki, M.; D Souza, G.; Funchain, P.; Eng, C.; Gollin, S.M.; Hong, A.; Jung, Y.S.; Kruger, M.; Lewis, J. jr.; Morbini, P.; Landolfo, S.; Ritta, M.; Straetmans, J.; Szarka, K.; Tachezy, R.; et al.

Prevalence of HPV infection in racial-ethnic subgroups of head and neck cancer patients

[year of publication 2017, impact factor 5.072 ]

[267]

Sahr, K.E.; Taylor, W.M.; Daniels, B.P.; Rubin, H.L.; Jarolim, P.

The structure and organization of the human erythroid anion exchanger (AE1) gene

[year of publication 2006, impact factor 5.037]

[268]

Cmejlova, J.; Dolezalova, L.; Pospisilova, D.; Petrtylova, K.; Petrak, J.; Cmejla, R.

Translational efficiency in patients with Diamond-Blackfan anemia

[year of publication 2007, impact factor 5.032]

[269]

Smolej, L.; Andrys, C.; Pekova, S.; Schwarz, J.; Belada, D.; Zak, P.

Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia

[year of publication 2007, impact factor 5.032]

[270]

Pekova, S.; Baran-Marszak, F.; Schwarz, J.; Matoska, V.

Mutated or non-mutated? Which database to choose when determining the IgVH hypermutation status in chronic lymphocytic leukemia?

[year of publication 2007, impact factor 5.032]

[271]

Papageorgiou, D.N.; Karkoulia, E.; Amaral-Psarris, A.; Burda, P.; Kolodziej, K.; Demmers, J.; Bungert, J.; Stopka, T.; Strouboulis, J.

Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: evidence for co-repressor functions

[year of publication 2016, impact factor 5.018 ]

[272]

Podrazil, M.; Horvath, R.; Becht, E.; Rozkova, D.; Bilkova, P.; Sochorova, K.; Hromadkova, H.; Kayserova, J.; Vavrova, K.; Lastovicka, J.; Vrabcova, P.; Kubackova, K.; Gasova, Z.; Jarolim, L.; Babjuk, M.; Spisek, R.; Bartunkova, J.; Fucikova, J.

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

[year of publication 2015, impact factor 5.008]

[273]

Svobodova, K.; Lhotska, H.; Hodanova, L.; Pavlistova, L.; Vesela, D.; Belickova, M.; Vesela, J.; Brezinova, J.; Sarova, I.; Izakova, S.; Lizcova, L.; Siskova, M.; Jonasova, A.; Cermak, J.; Michalova, K.; Zemanova, Z.

Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution

[year of publication 2020, impact factor 5.006 ]

[274]

Riedelová-Reicheltová, Z.; Kotlín, R.; Suttnar, J.; Geierová, V.; Riedel, T.; Májek, P.; Dyr, J.E.

A novel natural mutation AalphaPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function

[year of publication 2013, impact factor 4.984 ]

[275]

Hrachovinova, I.; Rypackova, B.; Vyoral, D.

Lack of association between hemochromatosis and factor V Leiden mutations in the Czech population

[year of publication 2006, impact factor 4.983]

[276]

Riedel, T.; de Los Santos Pereira, A.; Táborská, J.; Riedelová, Z.; Pop-Georgievski, O.; Májek, P.; Pečánková, K.; et al.

Complement activation dramatically accelerates blood plasma fouling on antifouling poly(2-hydroxyethyl methacrylate) brush surfaces

[year of publication 2022, impact factor 4.979 ]

[277]

Bendickova, K.; Fric, J.

Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy

[year of publication 2020, impact factor 4.962 ]

[278]

Štikarová, J.; Suttnar, J.; Pimková, K.; Chrastinová-Mášová, L.; Čermák, J.; Dyr, J.E.

Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome

[year of publication 2013, impact factor 4.933 ]

[279]

Belickova, M.; Merkerova, M.D.; Stara, E.; Vesela, J.; Sponerova, D.; Mikulenkova, D.; Brdicka, R.; Neuwirtova, R.; Jonasova, A.; Cermak, J.

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population

[year of publication 2013, impact factor 4.933 ]

[280]

Hajsl, M.; Hlavackova, A.; Broulikova, K.; Sramek, M.; Maly, M.; Dyr, J.E.; Suttnar, J.

Tryptophan metabolism, inflammation, and oxidative stress in patients with neurovascular disease

[year of publication 2020, impact factor 4.932 ]


Quick contact

Head of Science and Research Division
Tel:+420 221 977 305

Deputy head of Science and Research Division
Tel:+420 221 977 648

Secretary
Tel:+420 221 977 144


Opening hours

Ambulance
Mo – Fr: 7:00–18:00
Weekends: 9:00–13:00

Donors
Mo – Fr: 7:00–10:30

Visitors
Inpatient department
Mo – Fr: 13:00–18:00

ICU and Transplant unit
Mo – Fr: 14:00–17:00

How to find us

map

Ústav hematologie a krevní transfuze
(​Institute of Hematology and Blood Transfusion)

U Nemocnice 2094/1
128 00 Praha 2

The nearest underground station: Karlovo náměstí (line B)

The nearest tram station: Karlovo náměstí (10, 16, 22), Moráň (3, 6, 10, 16, 18, 24)

The nearest bus station: U Nemocnice (148), Karlovo náměstí (176)

How to get here